First Bundibugyo Ebola vaccine to start human trials in the UK

Sky News

Human Trials Of New Ebola Vaccine Set To Begin In Uk 13562950

Scott_Wiener

JeromeAdamsMD

The Epoch Times

US State Department Tells Americans to Avoid Congo Due to Ebola

TheContinent

Ebola: Short-term panic, long-term neglect

Pambazuka News

Ebola: Who created this terrible virus and why?

STAT

After a critique from Rubio, WHO defends work on Ebola response

FoxNews

Reuters

Oxford Begins First Human Trial Bundibugyo Ebola Vaccine 2026 07 13

Oxford Academic

2026 07 13 Worlds First Phase I Bundibugyo Ebolavirus Vaccine Trial Launched By

Pharmaphorum

First trial of Bundibugyo Ebola vaccine starts in UK

Azertag

Uk_Begins_Trials_Of_Ebola_Vaccine_Developed_In_Just_Eight_Weeks 4315781

BusinessLine

Oxford Vaccine Group launches worlds first Phase I Bundibugyo ebolavirus vaccine trial

The Economic Times

First vaccine for Bundibugyo Ebola hits human trials in Oxford study

The Indian Express

Oxfords new Ebola vaccine enters first human trial: Serum Institute making over 6,20,000 doses

NDTV

Oxford Serum Institute Of India Launch Human Trials Of New Ebola Vaccine Against The Bundibugyo Strain 11768682

The Kenyan Wallstreet

Researchers Begin Ebola Vaccine Trials as Outbreak Spreads

The Seattle Times

First human trial of Bundibugyo Ebola vaccine begins

BBC News

UK starts first vaccine trial, eight weeks into Ebola emergency

Metaculus

Ebola Bundibugyo Case First Confirmed On Us Soil Before 2027

Robert F. Kennedy Jr.

Bill Cassidy

Mehmet Oz

Jay Bhattacharya

Jim O'Neill

Jason M. Goldman

Jesse L. Goodman

Kevin A. Ault

IDSA

Diana DeGette

Caitlin Rivers

Andrew Racine

Robert Goldstein

WLBT3

West Coast Health Alliance

Sean O'Leary

UC Berkeley School of Public Health

Marty Makary

"This decision protects children, respects families, and rebuilds trust in public health."

"This [2026] decision recommits HHS to all three [transparency, rigorous science, and respect for families]."

"This decision commits NIH, CDC, and FDA to gold standard science, greater transparency, and ongoing reassessment as new data emerge."

"No family will lose access.This [2026] framework empowers parents and physicians to make individualized decisions based on risk, while maintaining strong protection against serious disease."

"The data support a more focused schedule that protects children from the most serious infectious diseases while improving clarity, adherence, and public confidence."

“I think that a reduced schedule is going to endanger children and lay the groundwork for a resurgence in preventable disease.”

“Changing the pediatric vaccine schedule based on no scientific input on safety risks and little transparency will cause unnecessary fear for patients and doctors, and will make America sicker.”

“There will be more diseases, more infection, more hospitalizations.”

Will Secretary Kennedy's US Childhood Vaccine Schedule Overhaul Risk Public Health?

Johns Hopkins Bloomberg School of Public Health

Avril Benoit

Ashish Jha

Stefano M. Bertozzi

Lawrence Gostin

Atlas Institute

Thomas J Bollyky

Steve Cohen

Tom Frieden

Jesse Bump

"If the U.S. withdraws from the WHO, it would severely weaken global health initiatives, disrupt pandemic preparedness efforts, and diminish U.S. influence over international health policy."

"If the United States is no longer a member of WHO, Americans around the world would be more susceptible to disease, but they could also carry it back to the United States and infect multitudes."

"It means we are going to see a lot more disease outbreaks become regional and global, and we will see more disease outbreaks from other countries coming into the U.S."

"The bottom line is that withdrawing from the WHO makes Americans and the world less safe."

"Public health disasters that don't have to happen will happen, because those capacities aren't there anymore [because of the US withdrawal from the WHO]."

"President Trump's decision to withdraw from the WHO could have life-threatening consequences for people in the humanitarian contexts where we work as well as in the US."

Will the US Withdrawal from the WHO Affect Public Health?

The University of Oxford has launched the world's first Phase I clinical trial of a vaccine against Bundibugyo ebolavirus, 57 days after the WHO declared the outbreak a public health emergency of international concern.

The University of Oxford has launched the world's first Phase I clinical trial of a vaccine against Bundibugyo ebolavirus, 57 days after the WHO declared the outbreak a public health emergency of international concern.

The Bundibugyo outbreak is now the third-largest Ebola outbreak on record, with 1,926 confirmed cases and 702 deaths across five provinces in the DRC as of July 11, and 20 cases including two deaths confirmed in Uganda on July 12.

The Bundibugyo outbreak is now the third-largest Ebola outbreak on record, with 1,926 confirmed cases and 702 deaths across five provinces in the DRC as of July 11, and 20 cases including two deaths confirmed in Uganda on July 12.

The BD-Ebov trial will enroll 50 healthy adults aged 18 to 55 in Oxford to assess the safety and immune response of the ChAdOx1 BDBV vaccine, which uses the same viral vector platform as the Oxford/AstraZeneca COVID-19 vaccine.

The BD-Ebov trial will enroll 50 healthy adults aged 18 to 55 in Oxford to assess the safety and immune response of the ChAdOx1 BDBV vaccine, which uses the same viral vector platform as the Oxford/AstraZeneca COVID-19 vaccine.

The Serum Institute of India manufactured and stockpiled approximately 620,000 doses of the ChAdOx1 BDBV vaccine candidate within two weeks and supplied 4,000 investigational doses for the Phase I trial.

The Serum Institute of India manufactured and stockpiled approximately 620,000 doses of the ChAdOx1 BDBV vaccine candidate within two weeks and supplied 4,000 investigational doses for the Phase I trial.

CEPI committed $8.6 million to advance the ChAdOx1 BDBV vaccine programme, with the bulk of its broader Bundibugyo vaccine funding — $50 million — earmarked for an mRNA vaccine being developed by Moderna.

CEPI committed $8.6 million to advance the ChAdOx1 BDBV vaccine programme, with the bulk of its broader Bundibugyo vaccine funding — $50 million — earmarked for an mRNA vaccine being developed by Moderna.

Preparations are underway for additional clinical studies in Uganda, pending regulatory approval, through partnerships with the Medical Research Council/Uganda Virus Research Institute and the London School of Hygiene and Tropical Medicine Uganda Research Unit.

Preparations are underway for additional clinical studies in Uganda, pending regulatory approval, through partnerships with the Medical Research Council/Uganda Virus Research Institute and the London School of Hygiene and Tropical Medicine Uganda Research Unit.

First Ebola vaccine to start human trials in the UK

First Ebola vaccine to start human trials in the UK

The Controversies

Jr.

Makary

Bhattacharya

Oz

O'Neill

Rivers

Cassidy

Goodman

Institute

Cohen

Jha

Frieden

Bump

Benoit

Go Deeper

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters

First Ebola vaccine to start human trials in the UK

First Ebola vaccine to start human trials in the UK

The Controversies

Jr.

Makary

Bhattacharya

Oz

O'Neill

Rivers

Cassidy

Goodman

Institute

Cohen

Jha

Frieden

Bump

Benoit

Go Deeper

Sign Up for Our Free NewslettersSign Up for Our Free Newsletters

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters